RxDoctor Payments Data

Prakul Chandra, MD

Family Medicine · Millen, GANPI 1497911937

Payments from drug & device makers

$1,884in general payments, 2019–2025

Across 87 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$714
  • Otsuka America Pharmaceutical, Inc.$220
  • AbbVie$147
  • Philips North America LLC$96
  • Pfizer$93
  • Johnson & Johnson$81
  • plus $533 from 16 others

What the payments were for

  • Food & beverage$1,884100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,884 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$5,884
Medicare patients
27
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide115$197,952
EliquisApixaban140$89,027
MounjaroTirzepatide76$83,683
OzempicSemaglutide64$70,789
LinzessLinaclotide73$52,090
RexultiBrexpiprazole25$36,116
XareltoRivaroxaban79$35,118
JardianceEmpagliflozin24$30,076
Breo ElliptaFluticasone/Vilanterol64$29,238
EntrestoSacubitril/Valsartan26$21,011
JanuviaSitagliptin Phosphate13$20,533
BelsomraSuvorexant35$19,282
TrulicityDulaglutide18$17,797
Tresiba Flextouch U-100Insulin Degludec38$16,881
Tresiba Flextouch U-200Insulin Degludec11$16,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$714$268,740179 claims
Lilly USA, LLCMounjaro, Trulicity$61$101,48194 claims
PfizerEliquis$93$89,027140 claims
AbbVieLinzess$147$52,09073 claims
Otsuka America Pharmaceutical, Inc.Rexulti$220$36,11625 claims
Johnson & JohnsonXarelto$81$35,11879 claims
NovartisEntresto$42$21,01126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Millen

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →